Difference between revisions of "CERNA3"

From LncRNAWiki
Jump to: navigation, search
Line 1: Line 1:
 +
 
==Annotated Information==
 
==Annotated Information==
−
===Approved Symbol===
+
===Name===
−
CERNA3
+
CERNA3:competing endogenous lncRNA 3 for miR-645
−
===Approved Name===
+
 
−
competing endogenous lncRNA 3 for miR-645
+
CTA<ref name="ref1" />
−
===Previous Symbols===
+
===Characteristics===
−
_
+
 
−
===Synonyms===
+
 
−
CTA
+
===Function===
−
===Chromosome===
+
Low expression of lncRNA CTA is significantly associated with the advanced clinical stage, tumor size and the malignant progression of osteosarcoma. In addition, osteosarcoma patients with low lncRNA CTA expression show a worse prognosis when compared with those with high 
−
8q12.1
+
level of lncRNA CTA.<ref name="ref1" />
−
===RefSeq ID===
+
Overexpression of lncRNA CTA markedly enhanced DOX-induced (doxorubicin) apoptosis and inhibition of proliferation in osteosarcoma cells, MG63 and Saos-2 cells. moreover, lncRNA CTA exerts a synergic effect with DOX in increasing the levels of Caspase 3 and in decreasing the levels of Bcl-2 and in growth inhibition of osteosarcoma cells in nude mice.<ref name="ref1" />
−
_
+
===Regulation===
−
===OMIM ID===
+
Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells.
−
_
+
Bioinformatic analysis shows that lncRNA CTA is a direct target of miR-21<ref name="ref1" />
−
===RefSeq(supplied by NCBI)===
+
===Diseases===
−
XR_001745918
+
Osteosarcoma<ref name="ref1" />
−
===pubmed IDs===
+
===Expression===
−
28415557
+
CTA's expression is significantly decreased in osteosarcoma tumor tissues compared with adjacent tissues.<ref name="ref1" />
−
===Disease===
+
===Sequence===
−
Osteosarcoma
+
>XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA
 +
<dnaseq>AGAGGCGGTCGCACAAGGGCGAGCTGGAGCACTAGTGGAGTTGGCGGGAAAGGCACGGCTGCGGGCGCCC
 +
CCTGTCCGCACGGAGGAGCCGAAGTCCCGCAGGGTGGGGTCCCCGCCTGCGCCGAGAGGGCCACCTGGTC
 +
GAGAGAACAGGCGACACGGAAACCTGAGAAACTCCTCTGTCTGGTGCACCTAACCCTCTTCCTCATAAAG
 +
TGCACACGAACTCTGGTTTTTCCGTTGCAAATTTTGCTTTCTACATAGACCATACCATTCGTTGCTCTCT
 +
GAGGATGAGCTCCTGGCTTCCCAGTCCAGCAGAAGTATCTACATCTATTTCTGGAAAGGACCTGAACTTG
 +
GCTTCTCGTCCTTCTGGAAAGTGAGGCGAAAATGCCAGGCTGCGCAGCTATCCTGAGGCCCGGCCTGGAA
 +
CCTGGCTAGCCACCCAGTCCTGATACCTCATCTCCTTTCTGTTGGATAAAGTCATTGGATAAGATCCCCC
 +
AGGGTCTTCTTAATACTGAACATCTGTTCATAATCACATAAGTGACCAAGTATAGTGGAAAACCCGAATG
 +
GTCAACTGAGCTGAGCAGTGGGAGAGAGCGCAGGGCTTACCTCATCCTTTAAGTATTTGAGGAACTGGTG
 +
AACAAGTTAACTACTTTGATAGTAAACGAGGAAATTTCTTTATAGAGAAAAGCAAAATGTGGCCCAGCAG
 +
GTATGTGAAAAATGGCTGATGTGACTAGAACTAAGGAAACAAATGGTTAAGATAATATTAGACAAAAGTA
 +
ATGGAAATTTTTTTTTTTTGGAAAACAGTATGGAGGGTCCTCAAAAAAT</dnaseq>
 +
==Labs working on this lncRNA==
 +
* Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
 +
==References==
 +
<references>
 +
<ref name="ref1">
 +
Wang Z, Liu Z, Wu S. Long non-coding RNA CTA sensitizes osteosarcoma cells to
 +
doxorubicin through inhibition of autophagy. Oncotarget. 2017 May
 +
9;8(19):31465-31477.
 +
</ref>
 +
</references>

Revision as of 02:38, 10 August 2017

Annotated Information

Name

CERNA3:competing endogenous lncRNA 3 for miR-645

CTA[1]

Characteristics

Function

Low expression of lncRNA CTA is significantly associated with the advanced clinical stage, tumor size and the malignant progression of osteosarcoma. In addition, osteosarcoma patients with low lncRNA CTA expression show a worse prognosis when compared with those with high level of lncRNA CTA.[1] Overexpression of lncRNA CTA markedly enhanced DOX-induced (doxorubicin) apoptosis and inhibition of proliferation in osteosarcoma cells, MG63 and Saos-2 cells. moreover, lncRNA CTA exerts a synergic effect with DOX in increasing the levels of Caspase 3 and in decreasing the levels of Bcl-2 and in growth inhibition of osteosarcoma cells in nude mice.[1]

Regulation

Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells. Bioinformatic analysis shows that lncRNA CTA is a direct target of miR-21[1]

Diseases

Osteosarcoma[1]

Expression

CTA's expression is significantly decreased in osteosarcoma tumor tissues compared with adjacent tissues.[1]

Sequence

>XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA

000001 AGAGGCGGTC GCACAAGGGC GAGCTGGAGC ACTAGTGGAG TTGGCGGGAA AGGCACGGCT GCGGGCGCCC CCTGTCCGCA 000080
000081 CGGAGGAGCC GAAGTCCCGC AGGGTGGGGT CCCCGCCTGC GCCGAGAGGG CCACCTGGTC GAGAGAACAG GCGACACGGA 000160
000161 AACCTGAGAA ACTCCTCTGT CTGGTGCACC TAACCCTCTT CCTCATAAAG TGCACACGAA CTCTGGTTTT TCCGTTGCAA 000240
000241 ATTTTGCTTT CTACATAGAC CATACCATTC GTTGCTCTCT GAGGATGAGC TCCTGGCTTC CCAGTCCAGC AGAAGTATCT 000320
000321 ACATCTATTT CTGGAAAGGA CCTGAACTTG GCTTCTCGTC CTTCTGGAAA GTGAGGCGAA AATGCCAGGC TGCGCAGCTA 000400
000401 TCCTGAGGCC CGGCCTGGAA CCTGGCTAGC CACCCAGTCC TGATACCTCA TCTCCTTTCT GTTGGATAAA GTCATTGGAT 000480
000481 AAGATCCCCC AGGGTCTTCT TAATACTGAA CATCTGTTCA TAATCACATA AGTGACCAAG TATAGTGGAA AACCCGAATG 000560
000561 GTCAACTGAG CTGAGCAGTG GGAGAGAGCG CAGGGCTTAC CTCATCCTTT AAGTATTTGA GGAACTGGTG AACAAGTTAA 000640
000641 CTACTTTGAT AGTAAACGAG GAAATTTCTT TATAGAGAAA AGCAAAATGT GGCCCAGCAG GTATGTGAAA AATGGCTGAT 000720
000721 GTGACTAGAA CTAAGGAAAC AAATGGTTAA GATAATATTA GACAAAAGTA ATGGAAATTT TTTTTTTTTG GAAAACAGTA 000800
000801 TGGAGGGTCC TCAAAAAAT

Labs working on this lncRNA

  • Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Wang Z, Liu Z, Wu S. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget. 2017 May 9;8(19):31465-31477.
Retrieved from "https://ngdc.cncb.ac.cn/lncrnawiki1/index.php?title=CERNA3&oldid=1273426"